Ambroxol is a scavenger of hypochlorous acid and monochloramine.
Experimental studies have suggested that ambroxol, a drug clinically used to enhance pulmonary surfactant production, may also exert some anti-inflammatory effects, though specific mechanisms are not yet fully understood. Thus, potential scavenging properties of ambroxol towards the most toxic neutrophil-arising prooxidants hypochlorous acid and monochloramine were investigated. We have found that the drug at 25, 50 and 100 mumol/l exerted a significant, concentration-related antagonizing effect on both chlorine species, with a maximal specific activity detected against hypochlorous acid. These new pharmacological properties of ambroxol may play a role in vivo in disease entities characterized by white blood cell activation and uncontrolled oxidant generation, such as inflammatory/ischemic conditions.